Research agreement
Henderson Morley plc of Birmingham, UK agreed a collaborative research deal with the Australian Centre for Vaccine Development, (ACVD), part of the Queensland Institute of Medical Research, to develop a vaccine for preventing cytomegalovirus (CMV) disease, the most important preventable infectious disease of unborn children in the developed world.
The collaboration will use a combination of technologies from Henderson Morley and ACVD. Each party shall pay its own costs, and any new intellectual property arising out of the collaboration will be shared equally.
ACVD has expertise in the discovery of candidate vaccine antigens, vaccine production and the testing of potential vaccines and drugs at the cellular, animal model and clinical levels.
Henderson Morley’s technology platform involves the development of vaccines based upon non-replicating herpes viruses that are DNA free.
The collaborative project will be using a CMV polyepitope antigen developed by the team at ACVD, incorporated into Henderson Morley’s delivery vector, to produce the new vaccine.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
Follow where the public and private R&I money is going and which collaborative opportunities you can pursue.
